NAD+ restoration for cellular resilience
PrimaryMetroBiotech's central theory is that age-related decline or insufficiency in NAD+ can be therapeutically countered by proprietary oral NAD+ precursors such as MIB-626 and newer analogs such as MIB-725. By restoring and sustaining NAD+ availability, the intervention is expected to support mitochondrial function, gene regulation, and cellular resilience, which the company links to improved healthspan and treatment of age-related diseases.
Testable predictions are that treated humans should show increased circulating and tissue NAD+ or NAD-related metabolites, improved pharmacodynamic markers of NAD+ biology, and eventually better outcomes in age-related disease settings compared with placebo.
company website · Thu Jun 25 2026 15:03:04 GMT+0000 (Coordinated Universal Time) ·
SourcePopperian evaluation
Premise plausibility7.0
The core premise is credible: NAD+ is tied to mitochondrial metabolism, NAD+-dependent enzymes, and stress responses, and the theory makes a direct claim that oral precursors should raise NAD+ biology in humans. The weak point is the jump from NAD+ insufficiency to broad age-related disease benefit. That final bridge is plausible, but thin in the provided evidence.
Supporting evidence: The theory specifies a mechanistic chain: oral precursor absorption, conversion into NAD+ or related metabolites, restoration in circulating and tissue compartments, then downstream effects on mitochondrial function and gene regulation.; The evidence context rates the human circulating NAD+ prediction as high confidence, which is the most near-term and testable part of the theory.
Counter evidence: No supporting publication in the provided context directly links MIB-626 or MIB-725 to improved age-related disease outcomes.; The broad claim that restored NAD+ improves healthspan has low confidence in the reasoning graph.
Explanatory power4.0
The theory explains why NAD+ metabolites and pharmacodynamic markers might move after treatment. It does not yet explain clinical aging outcomes better than simpler alternatives, such as a biomarker shift without durable tissue benefit, tissue-specific metabolism, or downstream pathways that do not meaningfully change disease course. Right now, it explains a biochemical intervention better than it explains aging.
Supporting evidence: The proposed mechanism connects a drug input to measurable NAD+ pathway outputs in humans.; The reasoning graph includes downstream markers of NAD+ biology, which gives the theory more structure than a generic supplement claim.
Counter evidence: The provided publications appear unrelated to NAD+ restoration and do not strengthen the explanatory case for MetroBiotech's theory.; The clinical-outcome prediction is marked low confidence, which means the theory has not yet earned the healthspan part of its explanation.
Falsifiability8.0
This is the strongest Popperian feature. The theory can be wrong in plain ways: MIB-626 or MIB-725 could fail to raise circulating NAD+ metabolites versus placebo, fail to raise tissue NAD+ measures, fail to shift pharmacodynamic markers, or fail in age-related disease endpoints despite biomarker movement. The theory would be sharper if it named compartments, doses, time windows, and minimum effect sizes.
Supporting evidence: The prediction that treated humans should show increased circulating NAD+ or NAD-related metabolites versus placebo is concrete and experimentally testable.; The theory also predicts tissue NAD+ changes, pharmacodynamic marker changes, and clinical benefit in age-related disease settings.
Counter evidence: The current formulation does not state a numeric threshold for a meaningful NAD+ increase.; The clinical prediction says outcomes should improve eventually, which leaves too much room to move the goalposts unless trials predefine endpoints and timing.
Reasoning tree
premiseAge-related decline or insufficiency in NAD+ is a therapeutically relevant contributor to reduced cellular resilience and age-related disease biology.
medium confidence
assumptionassumes
Oral proprietary NAD+ precursors such as MIB-626 and newer analogs such as MIB-725 can be absorbed and converted into NAD+ or NAD-related metabolites in humans.
medium confidence
derivationimplies
Administering MIB-626 or MIB-725 should restore and sustain NAD+ availability in relevant circulating and tissue compartments.
medium confidence
derivationimplies
Restored NAD+ availability should support mitochondrial function.
medium confidence
derivationimplies
Improved mitochondrial function and NAD+-dependent gene regulation should increase cellular resilience.
medium confidence
derivationimplies
Improved cellular resilience should translate into improved healthspan and treatment benefit in age-related diseases.
low confidence
predictionpredicts
In age-related disease settings, treated humans should eventually show better clinical outcomes than placebo-treated humans.
low confidence
project_implicationrequires
The project should prioritize human studies that measure NAD+ restoration, downstream pharmacodynamic effects, and clinical outcomes in age-related disease populations.
medium confidence
derivationimplies
Restored NAD+ availability should support NAD+-dependent gene regulation.
medium confidence
predictionpredicts
Humans treated with MIB-626 or MIB-725 should show increased circulating NAD+ or NAD-related metabolites compared with placebo.
high confidence
predictionpredicts
Humans treated with MIB-626 or MIB-725 should show increased tissue NAD+ or NAD-related metabolites compared with placebo.
medium confidence
predictionpredicts
Treated humans should show improved pharmacodynamic markers of NAD+ biology compared with placebo.
medium confidence
Public endorsements
publicly endorses
David Sinclair publicly promotes MetroBiotech's NAD-booster program in his own social posts, describing MIB-626/NAD boosters as turning on the body's defenses, reporting human-study results as 'amazing,' and linking the approach to beneficial effects seen in mice. That goes beyond a neutral mention and aligns with the company's NAD+ restoration theory.
Evidence publication IDs: 1427998b-5add-4fb6-bc21-139708a96579, 554f16d3-9893-48fb-97f6-ec5fcc561325
silent
No relevant quote or publication ties this James Ellis to MetroBiotech or to NAD+ restoration for cellular resilience. The provided records appear unrelated or ambiguous, so there is no public evidence here of endorsement, mention, or contradiction.
silent
No provided quote or publication links Li-Huei Tsai to a public statement endorsing, mentioning, or contradicting MetroBiotech's NAD+ restoration theory. The supplied records do not show her discussing this theory directly.
silent
The provided evidence does not contain a public statement from Lindsay Wu endorsing, mentioning, or contradicting MetroBiotech's NAD+ restoration theory. The records show affiliations, financial interests, and related NAD(P)+ research context, but no attributable public comment by Wu on this specific company theory.
silent
The provided evidence contains no relevant public statement from Nick Lane about MetroBiotech, NAD+ restoration, MIB-626, or the company’s causal theory. The listed records appear unrelated or are false-positive name matches.
Oral precursor metabolic flux into tissue NAD+
MetroBiotech's metabolic flux research program tests the theory that orally administered NAD+ precursors such as NMN or NAM are absorbed, metabolized, and incorporated into NAD+ pools in humans, including in muscle tissue. This is a mechanistic bridge claim: the company's therapeutics can only plausibly affect aging-linked biology if oral dosing raises relevant NAD+ metabolites in blood and target tissues.
Testable predictions are that labeled or unlabeled oral precursors should increase NAD+ production or related metabolites in blood, urine, stool, and muscle biopsy samples, with measurable differences by age group, precursor type, dose, or duration.
company website · Thu Jun 25 2026 15:03:04 GMT+0000 (Coordinated Universal Time) ·
SourcePopperian evaluation
Premise plausibility7.0
The premise is biologically credible: oral NMN and NAM can enter human metabolism, and the theory follows a coherent chain from absorption to metabolite handling to tissue NAD+ pools. The weaker step is muscle incorporation. Blood or urine changes can show exposure and metabolism, but they do not by themselves prove that target tissues raise NAD+ in a way that matters for aging-linked biology.
Supporting evidence: The theory names specific oral precursors, NMN and NAM, and links them to measurable NAD+ metabolites.; The reasoning chain separates absorption, metabolism, tissue incorporation, and therapeutic plausibility, which makes the mechanism internally coherent.; Muscle biopsy sampling is named directly, so the key tissue claim is at least addressable.
Counter evidence: The supplied evidence nodes list no supporting publication IDs for the NAD+ claims.; Blood, urine, and stool metabolite changes could reflect absorption and clearance without meaningful NAD+ elevation in muscle.; The claim that raising tissue NAD+ is necessary for aging-linked effects remains an assumption in the evidence context.
NAD+ precursor therapy for kidney injury and inflammation
MetroBiotech's COVID-19 acute kidney injury program proposes that MIB-626 may protect against worsening kidney function and attenuate inflammatory response in adults with COVID-19-associated stage 1 acute kidney injury. The implied causal mechanism is that NAD+ restoration improves cellular stress resistance and metabolic resilience during acute inflammatory and mitochondrial stress.
Testable predictions are that MIB-626-treated patients should have smaller longitudinal increases in serum creatinine, lower progression of acute kidney injury, reduced inflammatory markers, and increased blood NAD+ or NAD-related metabolites compared with placebo.
company website · Thu Jun 25 2026 15:03:04 GMT+0000 (Coordinated Universal Time) ·
SourcePopperian evaluation
Premise plausibility6.0
The premise is biologically credible but still under-proven in this exact setting. NAD+ metabolism is tied to mitochondrial stress handling and cellular repair, so an NAD+ precursor could plausibly help kidney cells under acute inflammatory stress. The weak link is patient-specific: the evidence provided does not show that MIB-626 raises NAD+ metabolites in adults with COVID-19-associated stage 1 acute kidney injury, or that that change is enough to alter kidney outcomes.
Supporting evidence: The theory gives a coherent causal chain: MIB-626 increases NAD+ or related metabolites, NAD+ restoration improves stress resistance, and improved stress resistance reduces kidney-cell vulnerability.; The proposed readouts include both mechanism-linked biomarkers and clinical kidney measures, which fits the biology rather than floating above it.
Counter evidence: No supporting publication in the provided context directly tests MIB-626 in COVID-19-associated acute kidney injury.; The supplied publication list appears mostly unrelated to NAD+, kidney injury, or COVID-19 acute kidney injury.
Explanatory power4.0
The theory could explain better creatinine trajectories, lower AKI progression, and reduced inflammatory markers if those effects appear together with higher NAD+ metabolites. Right now, it mostly explains a hoped-for pattern, not observed evidence. COVID-19 kidney injury has many competing explanations: hemodynamics, viral illness severity, inflammation, thrombosis, nephrotoxic drugs, and baseline kidney reserve. Without trial results tying MIB-626 to both NAD+ restoration and kidney protection, the explanatory claim stays modest.
NAD+ support for mitochondrial bioenergetics
MetroBiotech's Friedreich's Ataxia and performance-oriented programs imply a causal theory that raising NAD+ with MIB-626 should improve mitochondrial-linked bioenergetics in tissues such as cardiac and skeletal muscle. The mechanism is that NAD+ is a core metabolic cofactor, so increasing NAD+ availability should improve cellular energy metabolism in disorders or contexts where mitochondrial function is impaired or limiting.
Testable predictions are that MIB-626-treated participants should show measurable changes in cardiac or skeletal muscle bioenergetics, exercise-related metabolism, endurance, or muscle performance, with corresponding increases in NAD+ pathway metabolites.
company website · Thu Jun 25 2026 15:03:04 GMT+0000 (Coordinated Universal Time) ·
SourcePopperian evaluation
Premise plausibility7.0
The premise is biologically credible: NAD+ is a core metabolic cofactor, and raising NAD+ metabolites could plausibly change energy metabolism in tissues with mitochondrial stress. The weak point is constraint. The theory assumes NAD+ availability is limiting in Friedreich's Ataxia or performance contexts, but the supplied evidence does not show that MIB-626 reaches cardiac or skeletal muscle at a level that changes bioenergetics.
Supporting evidence: The theory states that MIB-626 is intended to raise NAD+ availability.; The reasoning graph rates the premise that NAD+ is involved in cellular energy metabolism as high confidence.; The causal chain is internally coherent: raise NAD+, alter NAD+ pathway metabolites, then test cardiac or skeletal muscle bioenergetics.
Counter evidence: The key assumption that NAD+ availability constrains bioenergetics in these contexts is only medium confidence.; No supplied publication directly tests MIB-626, Friedreich's Ataxia, cardiac bioenergetics, skeletal muscle bioenergetics, endurance, or muscle performance.
Explanatory power3.0
The theory explains a proposed program logic better than it explains observed evidence. We have a plausible mechanism, but almost no relevant outcome data in the provided context. Without measured NAD+ metabolite increases plus linked changes in muscle or cardiac function, the theory cannot yet beat simpler explanations such as general metabolic noise, training effects, placebo effects in performance measures, or disease variability.
NAD+ biology for muscle performance and endurance
MetroBiotech's exercise and physical performance program implies that NAD+ precursor treatment could improve muscle strength, endurance, or adaptation to training by supporting mitochondrial function and energy metabolism. If true, MIB-626 or related NAD+ precursor dosing should produce measurable improvements in physical performance endpoints, potentially alone or combined with high-intensity multidimensional exercise training.
manual entry · Tue Jun 23 2026 06:02:34 GMT+0000 (Coordinated Universal Time)
Popperian evaluation
Premise plausibility6.0
The biological premise is credible at the broad level: NAD+ is tied to mitochondrial metabolism, and skeletal muscle performance depends heavily on energy handling. The weak point is tissue relevance. The provided evidence does not show that MIB-626, or any related NAD+ precursor, raises NAD+ in skeletal muscle at a level that changes strength, endurance, or training response.
Supporting evidence: The theory states a coherent chain: NAD+ precursor dosing could raise NAD+ availability, support mitochondrial function, and improve muscle performance or training adaptation.; The reasoning nodes identify muscle strength, endurance, exercise capacity, and adaptation to training as the relevant endpoint family.
Counter evidence: The evidence context says the provided publications do not directly evaluate NAD+ precursors, MIB-626, mitochondrial muscle biology, endurance, strength, or training adaptation.; The key tissue assumption, higher biologically relevant NAD+ availability in skeletal muscle, is asserted with medium confidence rather than shown here.
Explanatory power2.0
The theory explains very little in this evidence packet because there is no relevant performance evidence to explain. The cited publications concern mirtazapine for methamphetamine use disorder, tamarind extract docking for depression-related targets, pediatric vein catheterization, and juvenile idiopathic arthritis recommendations. None bears on NAD+ precursor effects in exercise physiology.
NAD+ restoration to protect kidney function during acute injury
The COVID-19 acute kidney injury program proposes that MIB-626 may prevent worsening kidney function and attenuate inflammatory response in adults with COVID-19 and stage 1 acute kidney injury. Mechanistically, the theory links NAD+ restoration to improved cellular stress handling during acute inflammatory and renal injury. Testable predictions include better longitudinal serum creatinine trajectories and reduced inflammatory response versus placebo.
manual entry · Tue Jun 23 2026 06:02:34 GMT+0000 (Coordinated Universal Time)
Popperian evaluation
Premise plausibility6.0
The premise is biologically credible at the sketch level: acute kidney injury stresses renal cells, COVID-19 can drive inflammatory injury, and NAD+ biology is plausibly tied to cellular stress handling. The weak point is directness. The supplied evidence does not show that MIB-626 restores NAD+ in the relevant kidney or inflammatory compartments, or that this restoration changes creatinine trajectories in COVID-19 stage 1 acute kidney injury. So the premise is plausible, but under-supported here.
Supporting evidence: The theory names a defined intervention, MIB-626, in adults with COVID-19 and stage 1 acute kidney injury.; The mechanism links NAD+ restoration to cellular stress handling during acute inflammatory and renal injury.; The proposed clinical effects are concrete: less worsening kidney function and lower inflammatory response.
Counter evidence: The evidence context states that the supplied publications do not directly report MIB-626, NAD+ restoration, COVID-19 acute kidney injury, serum creatinine trajectories, or renal inflammatory outcomes.; The key bridge from MIB-626 exposure to renal NAD+ restoration is listed as an assumption with medium confidence.
Explanatory power3.0
The theory has little explanatory power against the supplied evidence because there is no relevant observed treatment result to explain. It could explain better creatinine trajectories and reduced inflammation if those outcomes appear in a placebo-controlled trial, but that is still conditional. Right now, alternative explanations such as baseline AKI severity, COVID-19 course, fluid status, nephrotoxic drug exposure, and standard supportive care remain wide open.
Oral NAD+ precursor metabolic flux
A more specific mechanistic theory is that orally administered NAD+ precursors are absorbed and metabolized into NAD+ in humans, including in muscle and other tissues. If this theory is correct, labeled or unlabeled NMN/NAM dosing should produce measurable increases in NAD+ and related metabolites in blood, urine, stool, and muscle biopsy samples, with older adults showing pharmacodynamic evidence of NAD+ repletion after short-term treatment.
manual entry · Tue Jun 23 2026 06:02:34 GMT+0000 (Coordinated Universal Time)
Popperian evaluation
Premise plausibility7.0
The premise is biologically credible: oral NAD+ precursors can plausibly enter human metabolism, and the theory names NAD+ and related metabolites as the readout. The weaker part is tissue reach. Blood and urine changes are easier to believe than a clear rise in muscle NAD+ after short-term dosing, because circulation and excretion can move without proving durable intracellular repletion.
Supporting evidence: The reasoning chain states that orally administered NAD+ precursors are absorbed in humans.; The theory predicts measurable NAD+ and related metabolite changes in blood, urine, stool, and muscle biopsy samples.; The project implication correctly identifies multi-compartment metabolomics as the required test.
Counter evidence: The provided reasoning nodes have no supporting publication IDs.; The theory assumes metabolite increases after dosing validly indicate flux into NAD+ pools, but that assumption is only medium confidence.; Muscle repletion is a stronger claim than absorption, and the supplied context gives no direct biopsy data.
Explanatory power5.0
The theory explains a specific pattern: NAD+ precursor dosing should move NAD+ pathway metabolites across several human sample types. But with the evidence supplied here, it does not yet beat simpler alternatives. A rise in blood or urine metabolites could reflect absorption, first-pass metabolism, renal clearance, or transient spillover rather than meaningful NAD+ repletion inside muscle.
Next-generation NAD+ analogs for age-related disease
MetroBiotech's MIB-725 program extends the same NAD+ biology theory to newer proprietary NAD+ analog therapeutics. The causal claim is that optimized NAD+ restoration compounds may sustain or improve NAD-linked biology relevant to aging, metabolism, and age-related diseases, potentially improving on earlier precursor approaches.
Testable predictions are that MIB-725 should be tolerable in early human dosing, increase or modulate NAD-related pharmacodynamic markers, and show disease-relevant biological effects in later trials if NAD+ restoration is causally linked to the targeted age-related pathology.
company website · Tue Jun 02 2026 23:15:21 GMT+0000 (Coordinated Universal Time) ·
SourcePopperian evaluation
Premise plausibility6.0
The premise is credible at the biology level: NAD-linked pathways do connect to aging, metabolism, mitochondrial function, and stress responses. The weaker part is the jump from restoring NAD-related markers to treating age-related disease. The evidence supplied gives no MIB-725 human data, no tissue exposure data, and no disease endpoint, so the premise rests on a plausible mechanism rather than demonstrated therapeutic causality.
Supporting evidence: The theory specifies NAD-linked biology as relevant to aging, metabolism, and age-related diseases.; The stated predictions include tolerability, NAD-related pharmacodynamic marker changes, and later disease-relevant biological effects.
Counter evidence: No supporting publications are attached to the NAD+ reasoning nodes.; The provided publication list appears unrelated to MIB-725 or NAD+ analog therapeutics.; The theory assumes pharmacologically meaningful NAD+ restoration in relevant human tissues, but no tissue data are provided.
Explanatory power3.0
The theory explains what MetroBiotech hopes MIB-725 will do, but it does not yet explain observed disease benefit because no such observation is included. Marker movement, if shown, would still have competing explanations: exposure, metabolic compensation, or nonspecific pathway modulation. The causal claim needs a tighter bridge between NAD biology and a named pathology.
MIB-626 as an NAD+ precursor therapeutic
MetroBiotech's MIB-626 program is based on the claim that a proprietary NAD+ precursor can pharmacologically increase NAD+ availability in humans, rather than relying on dietary supplementation or indirect lifestyle effects. The implied causal mechanism is that increasing NAD+ substrate availability should replenish NAD-dependent cellular pathways involved in energy metabolism, mitochondrial function, gene regulation, and stress response.
Testable predictions are that MIB-626 dosing should produce measurable increases in blood NAD+ and related metabolites within days to weeks, should do so without unacceptable safety signals, and should support later trials testing whether NAD+ elevation translates into clinical outcomes in age-related or mitochondrial-linked conditions.
company website · Tue Jun 02 2026 23:15:21 GMT+0000 (Coordinated Universal Time) ·
SourcePopperian evaluation
Premise plausibility6.0
The premise is biologically credible at the first step: an NAD+ precursor can, in principle, raise measurable NAD+ or related metabolites in humans if it is absorbed and converted. The harder claim is tissue relevance. Blood NAD+ movement does not prove that mitochondria, nuclei, or stressed tissues receive enough NAD+ to change function. The theory is plausible, but it leans on two bridges that are still weak here: compartment access and clinical meaning.
Supporting evidence: The theory names a direct pharmacodynamic prediction: MIB-626 dosing should raise blood NAD+ and related metabolites within days to weeks.; The proposed pathway is internally coherent: precursor availability could feed NAD-dependent processes involved in energy metabolism, mitochondrial function, gene regulation, and stress response.; The program correctly treats pharmacodynamic NAD+ elevation and tolerability as prerequisites before claiming benefit.
Counter evidence: The evidence context gives no MIB-626 human trial result showing the predicted NAD+ increase.; Blood NAD+ and related metabolites are only proxy compartments; they may not track NAD+ availability in the tissues that matter for disease.; The link from higher NAD+ to clinical benefit in age-related or mitochondrial-linked conditions is marked low confidence.
